<DOC>
	<DOC>NCT00736333</DOC>
	<brief_summary>This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).</brief_summary>
	<brief_title>A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)</brief_title>
	<detailed_description>Patients selected by investigator according to clinical routine</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients with metastatic breast cancer History of hypersensitivity to Caelyx or its components Women who are pregnant or breastfeeding Patients with severe myelosuppression</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>